Skip to main content

Table 1 Baseline demographics and disease characteristics (full analysis set)

From: Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Parameter Total (N = 194)
Sex, male, n (%) 127 (65.5)
Race, n (%)  
 Caucasian 187 (96.4)
 Other 7 (3.6)
Age, years, mean (SD) 62.8 (7.9)
BMI, kg/m2, mean (SD) 26.7 (4.7)
Smoking status, n (%)  
 Ex-smoker 84 (43.3)
 Current smoker 110 (56.7)
Pack-years, mean (SD) 47.5 (21.5)
Severity of COPD (GOLD 2010), n (%)  
 Stage I 1 (0.5)
 Stage II 160 (82.5)
 Stage III 32 (16.5)
 Not assessable 1 (0.5)
Post-bronchodilator FEV1, % predicted, mean (SD) 61.6 (10.7)
Post-bronchodilator FEV1/FVC, %, mean (SD) 51.2 (9.1)
COPD Assessment Test, mean (SD) 15.9 (6.0)
  1. SD standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, GOLD Global Initiative for Chronic Obstructive Lung Disease, FEV 1 , forced expiratory volume in 1 s, FVC forced vital capacity